You should be able to taper to 30 milligrams
methadone daily, in less than a year, then convert to
Suboxone.
Suboxone does not build an increasing tolerance and does not appear to decrease testosterone drastically. Suboxone is considered to be less than ten percent as addictive as methadone.
A much higher percentage of Suboxone patients, than methadone patients become opiate free. Suboxone will be off patent and should be available as a less expensive generic medication,in less than two years.
I think the taper schedule they have recommended is a practical one, which might avoid the worst methadone withdrawal effects. You should be stable at least a week, on a methadone dose, before reducing it, if you are not receiving
clonidine, muscle relaxers, sleep meds and other detox medications.
Hormonal testing and treatment for testosterone,
estradiol,
progesterone and DHEA might also help you, with your detox and taper.
Try increasing
magnesium, to reduce your need for methadone.
This 2003 Yale School of Medicine study revealed oral magnesium megadoses increased pain relief and reduced opiate use, in methadone patients. Magnesium appears to be reducing overfiring of NMDA glutamate receptors, which are involved in pain memory, and can also relax muscle spasms. Prolonged constipation produced by opiate use may also be reduced with magnesium supplementation.
J Addict Dis. 2003;22(2):49-61.
A preliminary, controlled investigation of magnesium L-aspartate hydrochloride for illicit
cocaine and opiate use in methadone-maintained patients.
Margolin A, Kantak K, Copenhaver M, Avants SK.
Yale University School of Medicine, Department of Psychiatry, Substance Abuse Center, New Haven, CT 06519, USA.
Based on pre-clinical studies suggesting that magnesium (Mg) reduces cocaine self-administration and potentiates the antinociceptive effects of
morphine, we conducted a preliminary randomized clinical trial investigating Mg for the treatment of illicit cocaine and opiate use. Eighteen methadone-maintained patients who used illicit opiates and cocaine received either Mg (732 mg/day) or placebo for 12 weeks. Overall, findings showed that the
percentage of urine screens testing positive for opiates in the Mg group (22.6%) was half that of the placebo group (46.4%), p = .04; the difference was even greater in the "medication compliant" sample (Mg: 16.3%, placebo: 47.9%), p = .02. Cocaine craving was lower in the Mg compared to the placebo group, but there was no difference between groups in cocaine use. These preliminary findings suggest that Mg may have a beneficial effect for reducing illicit opiate use. It is possible that a higher dose of Mg than was used in this study may be needed to decrease cocaine use.